{"id":43011,"date":"2025-10-10T16:31:01","date_gmt":"2025-10-10T08:31:01","guid":{"rendered":"https:\/\/flcube.com\/?p=43011"},"modified":"2025-10-10T16:31:02","modified_gmt":"2025-10-10T08:31:02","slug":"beijing-luzhu-biotechnology-completes-u-s-phase-1-trial-of-lz901-demonstrating-strong-safety-and-immunogenicity","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43011","title":{"rendered":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity"},"content":{"rendered":"\n<p>Beijing Luzhu Biotechnology Co., Ltd. (<a href=\"https:\/\/www.google.com\/finance\/quote\/2480:HKG\">HKG: 2480<\/a>) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate <strong>LZ901<\/strong> in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-clinical-findings\">Clinical Findings<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Safety Profile<\/strong> \u2013 The LD arm reported mild, vaccine\u2011related adverse reactions in 4.35\u202f% of participants, while the HD arm and placebo group experienced no vaccine\u2011related events.<\/li>\n\n\n\n<li><strong>Immunogenicity<\/strong> \u2013 Both dose levels elicited robust antibody responses, surpassing those observed in the placebo group and meeting the prespecified immunogenicity endpoints.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-strategic-context\">Strategic Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Product Positioning<\/strong> \u2013 LZ901 is designed to prevent herpes zoster and its most common complication, post\u2011herpetic neuralgia, in adults 40\u202f+\u202fyears old.<\/li>\n\n\n\n<li><strong>Regulatory Status<\/strong> \u2013 The Phase\u202f3 study conducted in China achieved its predefined clinical objectives and produced the expected outcomes. A biologics license application (BLA) for LZ901 has been accepted by China\u2019s National Medical Products Administration (NMPA) and is currently under review.<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong> \u2013 With rising incidence of shingles among aging populations worldwide, LZ901 could fill a significant unmet need in both Chinese and global markets.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-commercial-outlook\">Commercial Outlook<\/h3>\n\n\n\n<p>Luzhu Biotechnology plans to leverage the U.S. Phase\u202f1 data to support its global regulatory strategy, with a view to submitting a BLA to the U.S. Food and Drug Administration (FDA) following the completion of Phase\u202f2\/3 trials. The company\u2019s partnership network and robust manufacturing capacity position it well to scale production once regulatory approvals are secured.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100901033_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2025100901033_c.\"><\/object><a id=\"wp-block-file--media-80aba512-f4a0-4040-b1a8-e3388c84904b\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100901033_c.pdf\">2025100901033_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/2025100901033_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-80aba512-f4a0-4040-b1a8-e3388c84904b\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43014,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,1640,1641,12],"class_list":["post-43011","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-2480","tag-luzhu-biotechnology","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate LZ901 in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43011\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity\" \/>\n<meta property=\"og:description\" content=\"Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate LZ901 in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43011\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-10T08:31:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-10T08:31:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity\",\"datePublished\":\"2025-10-10T08:31:01+00:00\",\"dateModified\":\"2025-10-10T08:31:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1005.webp\",\"keywords\":[\"Clinical trial results\",\"HKG: 2480\",\"Luzhu Biotechnology\",\"Vaccine\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43011#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43011\",\"name\":\"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1005.webp\",\"datePublished\":\"2025-10-10T08:31:01+00:00\",\"dateModified\":\"2025-10-10T08:31:02+00:00\",\"description\":\"Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate LZ901 in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43011\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1005.webp\",\"width\":1080,\"height\":608,\"caption\":\"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43011#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity - Insight, China&#039;s Pharmaceutical Industry","description":"Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate LZ901 in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43011","og_locale":"en_US","og_type":"article","og_title":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity","og_description":"Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate LZ901 in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.","og_url":"https:\/\/flcube.com\/?p=43011","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-10T08:31:01+00:00","article_modified_time":"2025-10-10T08:31:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43011#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43011"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity","datePublished":"2025-10-10T08:31:01+00:00","dateModified":"2025-10-10T08:31:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43011"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43011#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp","keywords":["Clinical trial results","HKG: 2480","Luzhu Biotechnology","Vaccine"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43011#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43011","url":"https:\/\/flcube.com\/?p=43011","name":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43011#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43011#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp","datePublished":"2025-10-10T08:31:01+00:00","dateModified":"2025-10-10T08:31:02+00:00","description":"Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase\u202f1 clinical trial of the recombinant herpes zoster vaccine candidate LZ901 in the United States has been successfully completed. The study enrolled healthy adults aged 40\u202fand older and evaluated both high\u2011dose (HD) and low\u2011dose (LD) formulations against placebo.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43011#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43011"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43011#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp","width":1080,"height":608,"caption":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43011#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Beijing Luzhu Biotechnology Completes U.S. Phase\u202f1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43011"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43011\/revisions"}],"predecessor-version":[{"id":43015,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43011\/revisions\/43015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43014"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}